Latest from MSKCC

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung cancer.
Daniel Gomez, MD, provides insight on the different treatment approaches under exploration for patients with oligometastatic disease.
Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).
Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses future treatment strategies in early-stage non–muscle invasive bladder cancer.
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.
Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.
Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing work with immunotherapy in patients with advanced ovarian cancer.
Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.
Publication Bottom Border
Border Publication
x